Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT02811497
Title Study of Azacitidine and Durvalumab in Advanced Solid Tumors (METADUR)
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors University Health Network, Toronto

Her2-receptor negative breast cancer

ovary epithelial cancer

colorectal cancer

Advanced Solid Tumor


Azacitidine + Durvalumab

Age Groups: adult | senior
Covered Countries CAN

No variant requirements are available.